司美格鲁肽联合二甲双胍对2型糖尿病伴腹型肥胖患者胰岛功能及糖代谢指标的影响
CSTR:
作者:
作者单位:

濮阳市人民医院内分泌科,河南濮阳 457000

作者简介:

夏雪,E-mail:18539367788@163.com

通讯作者:

中图分类号:

R587.1

基金项目:


Effects of smeglutide combined with metformin on islet function and glucose metabolism in patients with type 2 diabetes mellitus and abdominal obesity
Author:
Affiliation:

Department of Endocrinology, Puyang People's Hospital, Puyang Henan 457000 , China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨司美格鲁肽联合二甲双胍对2型糖尿病(T2DM)伴腹型肥胖患者的影响。方法 以随机数字表法将2022年8月至2024年8月在濮阳市人民医院就诊的98例T2DM伴腹型肥胖患者分为两组,每组49例。对照组采取二甲双胍治疗,观察组在此基础上联合司美格鲁肽治疗。治疗12周后,对比两组胰岛功能、糖代谢指标、体质量指数(BMI)、不良反应。结果 对比治疗前,治疗后两组空腹胰岛素(FINS)、空腹C肽(FC-P)、胰岛素抵抗指数(HOMA-IR)、空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、BMI均降低,且观察组低于对照组;两组胰岛素分泌指数(HOMA-β)增加,且观察组比对照组高,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 司美格鲁肽联合二甲双胍应用于T2DM伴腹型肥胖患者,有助于改善胰岛功能及糖代谢指标,管理体质量,且具有良好安全性。

    Abstract:

    Objective To investigate the effect of smeglutide combined with metformin on patients with type 2 diabetes mellitus (T2DM) and abdominal obesity.Methods A total of 98 patients with T2DM and abdominal obesity treated in Puyang People's Hospital from August 2022 to August 2024 were randomly divided into two groups, with 49 cases in each group. The control group was treated with metformin, and the observation group was treated with smeglutide and metformin. After 12 weeks of treatment, islet function, glucose metabolism indexes, body mass index (BMI), and adverse reactions were compared between the two groups.Results Compared with before treatment, both groups showed a decrease in fasting insulin (FINS), fasting C-peptide (FC-P), insulin resistance index (HOMA-IR), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycated hemoglobin (HbA1c), and BMI after treatment, and data of the observation group were lower than those of the control group, After treatment, the insulin secretion index (HOMA-β) of the two groups were increased, and data of the observation group were higher than that of the control group, with statistically significant (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of smeglutide combined with metformin in patients with T2DM and abdominal obesity can help improve islet function and glucose metabolism indicators, manage body weight, and has good safety.

    参考文献
    相似文献
    引证文献
引用本文

夏雪,施伟生,郭敬.司美格鲁肽联合二甲双胍对2型糖尿病伴腹型肥胖患者胰岛功能及糖代谢指标的影响[J].天津药学,2025,37(1):28-31.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-02-18
  • 出版日期:
文章二维码
您是第位访问者
天津药学 ® 2025 版权所有
技术支持:北京勤云科技发展有限公司